Dato-DXd for lung cancer: what patients should know

Its full name is datopotamab deruxtecan. Eligibility depends on the tumour type, stage, confirmed EGFR result and treatment history; it is not a general treatment for every lung cancer. In its approved lung cancer use, patients have already received EGFR-directed treatment and platinum-based chemotherapy.

Dato-DXd combines an antibody that recognises Trop-2 on cancer cells with a linked chemotherapy payload. After binding, the medicine enters the cell and releases the payload, which disrupts DNA handling and can kill the cell. This targeted delivery does not prevent effects on healthy tissues.

The medicine is given by intravenous infusion at a cancer centre. Genomic tumour profiling helps establish the EGFR mutation, while previous treatment records show whether this option fits the approved sequence. Scans, blood tests and symptom reviews are used to assess the cancer and manage toxicity.

Before starting, tell the team about existing lung or breathing problems, eye conditions, pregnancy, breastfeeding and every medicine or supplement you use. Follow the prescribed eye-care plan and attend eye checks. Report dry, painful, red or blurred eyes early because treatment changes may be needed.

Mouth soreness can make eating and drinking difficult. Use the mouth-care routine recommended by the clinic, choose gentle foods when the mouth is tender, and report ulcers or pain promptly. The team may give medicines before an infusion to reduce nausea or an infusion reaction; take supportive medicines as directed rather than waiting for symptoms to become severe.

Contact the oncology team immediately for a new or worsening cough, shortness of breath, fever, chest tightness or wheezing. Dato-DXd can cause inflammation of lung tissue, called interstitial lung disease or pneumonitis, and early assessment matters. Do not assume breathing changes are simply due to the cancer.

Seek emergency help for severe breathing difficulty, blue or grey lips, collapse, or swelling of the face or throat. During an infusion, tell staff at once about flushing, chills, dizziness, itching or breathing changes. Urgent eye pain or a sudden change in vision also needs immediate clinical advice.

Ask which EGFR alteration was found, how earlier EGFR-directed therapy and chemotherapy affect eligibility, and what the treatment aims to achieve in your situation. Request a clear plan for scans, blood tests, eye assessments and mouth care, plus the direct number for reporting breathing symptoms between visits.

Discuss how the team will distinguish drug-related lung inflammation from infection or cancer symptoms, what may lead to an infusion delay or dose change, and whether any current medicines should be adjusted. If pregnancy is possible for you or a partner, ask what contraception guidance applies during and after treatment.